Literature DB >> 19542257

The metabolic syndrome in patients with chronic bronchitis and COPD: frequency and associated consequences for systemic inflammation and physical inactivity.

Henrik Watz1, Benjamin Waschki2, Anne Kirsten3, Kai-Christian Müller4, Gunther Kretschmar3, Thorsten Meyer5, Olaf Holz4, Helgo Magnussen2.   

Abstract

BACKGROUND: The metabolic syndrome is a condition frequently found among individuals > 60 years of age. It predisposes affected individuals to systemic inflammation and physical inactivity. Systemic inflammation and physical inactivity are relevant extrapulmonary markers of morbidity and mortality in patients with COPD. Here, we studied the following: (1) the frequency of the coexisting metabolic syndrome in patients with chronic bronchitis (CB) and COPD of different severities; and (2) its association with systemic inflammation and physical inactivity.
METHODS: In 30 patients with CB (normal spirometry finding) and in 170 patients with COPD (Global Initiative for Chronic Obstructive Lung Disease [GOLD] stages I to IV), we measured the characteristics of the metabolic syndrome, systemic inflammation (high-sensitivity C-reactive protein [hs-CRP], interleukin-6, fibrinogen), and the physical activity level.
RESULTS: The frequencies of the metabolic syndrome in patients with CB, GOLD stages I, II, III, and IV, were 53%, 50%, 53%, 37%, and 44%, respectively (average, 47.5%). The levels of hs-CRP and interleukin-6 were significantly increased in patients with the metabolic syndrome, while the physical activity level was significantly decreased. Multivariate linear regression analyses revealed metabolic syndrome, physical activity level, and CB/GOLD stages to be independent predictors of hs-CRP and interleukin-6 levels, and physical activity level to be a predictor of fibrinogen levels.
CONCLUSIONS: In our study, almost one-half of the patients with CB/COPD had coexisting metabolic syndrome, with a slightly lower frequency in patients with severe COPD. The coexisting metabolic syndrome is associated with an increase in the levels of some systemic inflammatory markers and physical inactivity, independent of lung function impairment.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19542257     DOI: 10.1378/chest.09-0393

Source DB:  PubMed          Journal:  Chest        ISSN: 0012-3692            Impact factor:   9.410


  80 in total

1.  Alveolar-capillary adaptation to chronic hypoxia in the fatty lung.

Authors:  C Yilmaz; P Ravikumar; D Gyawali; R Iyer; R H Unger; C C W Hsia
Journal:  Acta Physiol (Oxf)       Date:  2014-11-25       Impact factor: 6.311

2.  COPD and osteoporosis: something more than a comorbidity.

Authors:  Claudio Tantucci
Journal:  Endocrine       Date:  2012-08       Impact factor: 3.633

3.  The Correlation of Serum Brain Natriuretic Peptide and Interleukin-6 with Quality of Life Using the Chronic Obstructive Pulmonary Disease Assessment Test.

Authors:  Hassan Ghobadi; Mohammad Reza Aslani; Adalat Hosseinian; Esmaeil Farzaneh
Journal:  Med Princ Pract       Date:  2017-11-02       Impact factor: 1.927

4.  Feasibility and acceptability of active for life with COPD, an intervention to increase light physical activity in people with COPD.

Authors:  Janet L Larson; Katelyn E Webster
Journal:  Heart Lung       Date:  2020-01-31       Impact factor: 2.210

5.  Smokers with COPD Show a Shift in Energy and Nitrogen Metabolism at Rest and During Exercise.

Authors:  Olaf Holz; David S DeLuca; Stefan Roepcke; Thomas Illig; Klaus M Weinberger; Christian Schudt; Jens M Hohlfeld
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2020-01-06

6.  The Effect of a Short Duration, High Intensity Exercise Intervention on Gait Biomechanics in Patients With COPD: Findings From a Pilot Study.

Authors:  Jennifer M Yentes; Daniel Blanke; Stephen I Rennard; Nicholas Stergiou
Journal:  Chronic Obstr Pulm Dis       Date:  2014-05-06

Review 7.  Physiopathological relationship between chronic obstructive pulmonary disease and insulin resistance.

Authors:  Felipe Vilaça Cavallari Machado; Fabio Pitta; Nidia Aparecida Hernandes; Gisele Lopes Bertolini
Journal:  Endocrine       Date:  2018-03-06       Impact factor: 3.633

8.  Chronic obstructive pulmonary disease: effects beyond the lungs.

Authors:  Peter J Barnes
Journal:  PLoS Med       Date:  2010-03-16       Impact factor: 11.069

Review 9.  Systemic inflammation in chronic obstructive pulmonary disease: may adipose tissue play a role? Review of the literature and future perspectives.

Authors:  Ruzena Tkacova
Journal:  Mediators Inflamm       Date:  2010-04-20       Impact factor: 4.711

10.  Metabolic syndrome and associated factors in people with chronic obstructive pulmonary disease.

Authors:  Soo Kyung Park; Janet L Larson
Journal:  West J Nurs Res       Date:  2013-11-29       Impact factor: 1.967

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.